Published in Curr Opin Cardiol on January 01, 2011
Niacin Plus Statin to Prevent Vascular Events | NCT00120289
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE) | NCT00461630
The role of nutrition and body composition in peripheral arterial disease. Nat Rev Cardiol (2012) 0.84
Effects of paraoxonase activity and gene polymorphism on coronary vasomotion. EJNMMI Res (2011) 0.75
Local Inhibition of Macrophage and Smooth Muscle Cell Proliferation to Suppress Plaque Progression. Methodist Debakey Cardiovasc J (2016) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet (1975) 9.00
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med (2000) 4.35
Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys (1955) 3.63
Inflammation in atherosclerosis: transition from theory to practice. Circ J (2010) 2.98
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 2.97
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA (1988) 2.89
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand (1988) 2.86
Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation (2001) 2.71
Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest (1990) 2.55
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun (2003) 2.00
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol (2008) 1.97
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1998) 1.96
Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes (2005) 1.87
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol (2009) 1.66
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb (2010) 1.65
High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol (2010) 1.62
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis (2010) 1.37
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci (2006) 1.33
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res (2004) 1.31
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis (2009) 1.31
High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol (2004) 1.30
Extended-release niacin raises adiponectin and leptin. Atherosclerosis (2006) 1.27
Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab (2009) 1.25
The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart (2003) 1.24
Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol (2006) 1.19
Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation (2002) 1.18
Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol (2010) 1.15
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med (2009) 1.06
Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun (2005) 1.06
Nicotinic acid receptor subtypes and their ligands. Med Res Rev (2007) 0.98
Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol (1999) 0.97
Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep (2000) 0.93
The HALTS trial--halting atherosclerosis or halted too early? N Engl J Med (2009) 0.86
Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med (2009) 0.81
With the "universal definition," measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol (2011) 2.99
Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol (2004) 2.53
Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 tesla. J Am Coll Cardiol (2012) 2.38
Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 2.34
Early diagnosis of perioperative myocardial infarction after coronary bypass grafting: a study using biomarkers and cardiac magnetic resonance imaging. Ann Thorac Surg (2011) 2.27
Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2002) 2.13
Obesity and prostate cancer: a role for adipokines. Eur Urol (2007) 2.10
Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson (2012) 2.03
Dynamic changes of edema and late gadolinium enhancement after acute myocardial infarction and their relationship to functional recovery and salvage index. Circ Cardiovasc Imaging (2011) 1.97
In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med (2007) 1.90
Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla. J Am Coll Cardiol (2007) 1.86
Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol (2007) 1.78
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol (2009) 1.66
Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction. J Am Coll Cardiol (2014) 1.63
Plaque features associated with increased cerebral infarction after minor stroke and TIA: a prospective, case-control, 3-T carotid artery MR imaging study. JACC Cardiovasc Imaging (2012) 1.35
Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation (2012) 1.32
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis (2009) 1.31
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis (2003) 1.31
Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol (2012) 1.29
Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov (2008) 1.26
Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson (2014) 1.26
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging (2012) 1.18
Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation (2004) 1.12
Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci U S A (2012) 1.10
Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation (2013) 1.09
A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest (2008) 1.09
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis (2009) 1.08
In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmentation and T2 measurement of plaque components. J Cardiovasc Magn Reson (2013) 1.06
Quantification and 3D reconstruction of atherosclerotic plaque components in apolipoprotein E knockout mice using ex vivo high-resolution MRI. Arterioscler Thromb Vasc Biol (2004) 1.05
CMR for characterization of the myocardium in acute coronary syndromes. Nat Rev Cardiol (2010) 1.04
In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One (2010) 0.99
Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int (2008) 0.99
Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation (2005) 0.99
Diagnostic value of pre-contrast T1 mapping in acute and chronic myocardial infarction. JACC Cardiovasc Imaging (2013) 0.98
Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis (2007) 0.97
Reproducibility and accuracy of automated measurement for dynamic arterial lumen area by cardiovascular magnetic resonance. Int J Cardiovasc Imaging (2009) 0.97
Black-blood multicontrast imaging of carotid arteries with DANTE-prepared 2D and 3D MR imaging. Radiology (2014) 0.97
VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis. FASEB J (2011) 0.96
Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab Vasc Dis Res (2007) 0.94
Myocardial infarction causes inflammation and leukocyte recruitment at remote sites in the myocardium and in the renal glomerulus. Inflamm Res (2013) 0.94
Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: rational design through target quantification. Atherosclerosis (2011) 0.94
Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J Vasc Res (2008) 0.94
A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides (2009) 0.93
Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol (2009) 0.92
Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab (2010) 0.92
A leukocyte-mimetic magnetic resonance imaging contrast agent homes rapidly to activated endothelium and tracks with atherosclerotic lesion macrophage content. Arterioscler Thromb Vasc Biol (2012) 0.90
Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin. Peptides (2010) 0.90
Loss of fine structure and edge sharpness in fast-spin-echo carotid wall imaging: measurements and comparison with multiple-spin-echo in normal and atherosclerotic subjects. J Magn Reson Imaging (2011) 0.89
Clopidogrel and percutaneous coronary interventions. JAMA (2003) 0.89
High-resolution, multicontrast three-dimensional-MRI characterizes atherosclerotic plaque composition in ApoE-/- mice ex vivo. J Magn Reson Imaging (2004) 0.87
Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab (2006) 0.87
Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol (2011) 0.87
Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice. Am J Pathol (2013) 0.87
GPR109A and vascular inflammation. Curr Atheroscler Rep (2013) 0.87
Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart (2006) 0.86
Glucose induces and leptin decreases expression of uncoupling protein-2 mRNA in human islets. FEBS Lett (2002) 0.85
Adiponectin (15-36) stimulates steroidogenic acute regulatory (StAR) protein expression and cortisol production in human adrenocortical cells: role of AMPK and MAPK kinase pathways. Biochim Biophys Acta (2011) 0.84
Magnetic resonance imaging and computed tomography in assessment of atherosclerotic plaque. Curr Atheroscler Rep (2004) 0.83
Development and application of endothelium-targeted microparticles for molecular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.81
Chapter 4 - Applications of nanotechnology in molecular imaging of the brain. Prog Brain Res (2009) 0.81
Molecular MRI approaches to the detection of CNS inflammation. Methods Mol Biol (2011) 0.81
Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity. J Cardiovasc Magn Reson (2011) 0.80
Magnetic resonance imaging of brain inflammation using microparticles of iron oxide. Methods Mol Biol (2011) 0.80
Ischemic heart disease: comprehensive evaluation by cardiovascular magnetic resonance. Am Heart J (2011) 0.79
Atherosclerosis regression and high-density lipoproteins. Expert Rev Cardiovasc Ther (2010) 0.79
Exogenous microparticles of iron oxide bind to activated endothelial cells but, unlike monocytes, do not trigger an endothelial response. Theranostics (2013) 0.78
A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). EuroIntervention (2016) 0.78
Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease. Int J Cardiol (2013) 0.78
Target: ligand interactions of the vascular endothelium. Implications for molecular imaging in inflammation. Integr Biol (Camb) (2010) 0.78
Embolic myocardial infarction in atrial fibrillation: multiple territory injury revealed by cardiac magnetic resonance. Eur Heart J (2010) 0.78
Targeted molecular imaging of vascular inflammation in cardiovascular disease using nano- and micro-sized agents. Vascul Pharmacol (2012) 0.77
Targeting HDL-cholesterol to reduce residual cardiovascular risk. Curr Opin Lipidol (2012) 0.77
Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS One (2013) 0.77
The role of cardiovascular magnetic resonance in patients with acute coronary syndromes. Prog Cardiovasc Dis (2011) 0.77
Non-invasive imaging of carotid arterial restenosis using 3T cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2014) 0.77
Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol (2005) 0.77
Detection of brain pathology by magnetic resonance imaging of iron oxide micro-particles. Methods Mol Biol (2011) 0.77
Cardiometabolic interventions - focus on transcriptional regulators. Eur J Cardiovasc Med (2013) 0.76
Rheumatoid arthritis: RA--lowering cardiovascular risk with statins. Nat Rev Rheumatol (2010) 0.75
Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol (2017) 0.75
The influence of coronary plaque morphology assessed by optical coherence tomography on final microvascular function after stenting in patients with ST-elevation myocardial infarction. Coron Artery Dis (2016) 0.75
Macrophage detection in aortic aneurysm: the heat is on. Arterioscler Thromb Vasc Biol (2011) 0.75
Heparin administration leads to rapid decrease in plasma matrix metalloproteinase-9. Int J Cardiol (2012) 0.75
High-density lipoproteins and cardiovascular disease: the plots thicken. Heart (2012) 0.75
Magnetic resonance imaging of coronary atherosclerosis. Curr Atheroscler Rep (2003) 0.75
Atherosclerosis regression. Curr Treat Options Cardiovasc Med (2008) 0.75
Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)? Curr Opin Lipidol (2010) 0.75
MRI of acute vascular syndromes: the emerging role of cardiovascular MRI in the diagnosis and treatment of AMI and stroke. Expert Rev Cardiovasc Ther (2012) 0.75